study of medical treatment reactivity by the chemokine receptor (CXCR4)as 1st line treatment in patients with metastatic colorectal cancer

Phase 2

Recruiting

• Conditions: Colorectal Cancer

• Registration Number: JPRN-UMIN000008542
• Lead Sponsor: The Cancer Institute Hospital of JFCR

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-07-28
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Recruiting
• Sex: All
• Target Recruitment: 160

Inclusion Criteria

Not provided

Exclusion Criteria

1)Prior severe drug allergy 2) Be Administered or less than 7 days finished administration Compound Drug of tegafur,gimeracil and oteracil potassium 3) The anti-EGFR antibody (Panitumumab or Cetuximab) has been prescribed for the patient until now. 4) A patient with myelosuppression 5) Patients with large quantity of pleural effusion or ascites 6) Active infection 7) A patient with intestinal tract paralysis and ileus 8) A patient with jaundice 9) A patient with a critical renal damage or a liver damage 10) Under Flucytosine medication 11) severe pulmonary dysfunction 12)K-RAS mutation 13) Concerning pregnancy 14) Complication of cerebrovascular disease or symptoms within 1 years 15) Surgery, biopsy specimen with section or sutures within the past 4 weeks. Fine needle aspiration biopsy within 1 week 16) Administering antithrombotic drug within 10 days 17) Need to administrate or having anti-platelets therapy (including Methotrexate aspirin and NSAIDS 18) Diathesis of bleeding (history of hemoptysis, including cavitation and/or necrosis in lung metastasis confirmed by imaging), coagulopathy or abnormality of coagulation factor as INR>=1.5 19) active peptic ulcer 20) History of gastrointestinal perforation within 1 year 21) Traumatic fracture of unrecovery 22) Nephropathy that requires medication or transfusion or urine protein over +2 within 2 weeks examination 23) Uncontrollable hypertension 24) Uncontrollable diabetes mellitus 25) Patient with symptomatic cardiovascular disease or asymptomatic disease but have been treated (>=Grade 2 according to NCI-CTCAE ver.4). History of myocardial 26) History of hypersensitivity against fluorouracil or platinum agents. 27) History of organ transplantation 28)any other cases who are regarded as unsuitable for enrollment in the study by the investigator

Study & Design

• Study Type: Interventional
• Study Design: Not specified